Sugi Predict

Sugi Predict / Targets / CPT2

CPT2

Carnitine O-palmitoyltransferase 2, mitochondrial · P23786 · CPT2 on Sugi Atlas →

19,244 patent compounds predicted against CPT2, 11,174 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL750273 SCHEMBL750273 0.86 17/20
SCHEMBL750306 SCHEMBL750306 0.84 17/20
SCHEMBL749736 SCHEMBL749736 1.00 16/20
SCHEMBL750231 SCHEMBL750231 0.64 16/20
SCHEMBL749999 SCHEMBL749999 1.00 15/20
SCHEMBL750308 SCHEMBL750308 1.00 15/20
SCHEMBL750135 SCHEMBL750135 0.85 12/20
SCHEMBL750078 SCHEMBL750078 0.81 12/20
SCHEMBL750220 SCHEMBL750220 0.66 12/20
SCHEMBL750266 SCHEMBL750266 0.82 11/20
SCHEMBL750259 SCHEMBL750259 0.57 11/20
SCHEMBL750018 SCHEMBL750018 0.82 10/20
SCHEMBL750198 SCHEMBL750198 0.74 10/20
SCHEMBL750365 SCHEMBL750365 0.69 8/20
SCHEMBL749997 SCHEMBL749997 0.84 7/20
SCHEMBL750006 SCHEMBL750006 0.74 6/20
SCHEMBL727671 SCHEMBL727671 0.41 6/20
SCHEMBL750332 SCHEMBL750332 0.86 5/20
SCHEMBL164419 SCHEMBL164419 0.50 4/20
SCHEMBL166687 SCHEMBL166687 0.50 4/20

Clinical trials — most relevant to CPT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children PHASE4UNKNOWN
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis PHASE4UNKNOWN
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
Metabolic Manipulation in Chronic Heart Failure PHASE2COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans PHASE2RECRUITING
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders PHASE1COMPLETED
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension PHASE1COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)? PHASE1UNKNOWN
KETO-TUMOR: a Study on Brain Tumors and Central Obesity nanRECRUITING
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids nanCOMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates nanCOMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
Lactate Profile and Fat Oxidation During Exercise nanCOMPLETED
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) nanCOMPLETED
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism nanNO_LONGER_AVAILABLE
Ketogenic Diet Therapy for Autism Spectrum Disorder nanCOMPLETED
In and ex Vivo Mitochondrial Function of the Heart nanCOMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
KD Treatment for Super-refractory Status Epilepticus nanRECRUITING
Acylcarnitine Profile After Intensive Care nanUNKNOWN
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders nanCOMPLETED
REFUEL PCOS Study 1 nanUNKNOWN
Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CPT2 binder may also engage these)

ProteinNameSimilarity
Q60HG9 — 1.000 Q60HG9 →
P18886 — 1.000 P18886 →
Q2KJB7 — 1.000 Q2KJB7 →
P52825 — 1.000 P52825 →
Q5U3U3 — 0.999 Q5U3U3 →
Q7ZXE1 — 0.999 Q7ZXE1 →
Q6P4X5 — 0.998 Q6P4X5 →
CRAT Carnitine O-acetyltransferase 0.991 landscape →
P47934 — 0.990 P47934 →
Q704S8 — 0.989 Q704S8 →
P52826 — 0.985 P52826 →
O19094 — 0.984 O19094 →
P11466 — 0.982 P11466 →
Q63704 — 0.981 Q63704 →
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform 0.980 landscape →
Q924X2 — 0.980 Q924X2 →
B2ZGJ1 — 0.979 B2ZGJ1 →
Q8HY46 — 0.979 Q8HY46 →
Q9UKG9 — 0.979 Q9UKG9 →
P32738 — 0.977 P32738 →
Q9DC50 — 0.977 Q9DC50 →
Q03059 — 0.976 Q03059 →
Q68Y62 — 0.976 Q68Y62 →
P97742 — 0.975 P97742 →
Q90YJ9 — 0.975 Q90YJ9 →
P32198 — 0.975 P32198 →
P13222 — 0.974 P13222 →
CPT1B Carnitine O-palmitoyltransferase 1, muscle isoform 0.973 landscape →
Q58DK1 — 0.973 Q58DK1 →
P07668 — 0.969 P07668 →